[{"id":"714db3ca-404e-4222-9a0f-e2cca6ea14dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07483567","created_at":"2026-03-28T01:36:25.975Z","updated_at":"2026-03-28T01:36:25.975Z","phase":"Phase 2","brief_title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT07483567","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/30/2026","start_date":" 03/30/2026","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2026-03-19"},{"id":"b8f6cdd3-6953-45e6-a654-0d04207d6f01","acronym":"","url":"https://clinicaltrials.gov/study/NCT07481357","created_at":"2026-03-28T01:39:34.825Z","updated_at":"2026-03-28T01:39:34.825Z","phase":"Phase 1","brief_title":"A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT07481357","lead_sponsor":"Dong-A ST Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 02/01/2026","start_date":" 02/01/2026","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2026-03-18"},{"id":"488850a4-401a-418b-88e8-32f7b6c5f0dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038578","created_at":"2023-09-15T18:09:55.230Z","updated_at":"2025-02-25T13:41:43.311Z","phase":"Phase 2","brief_title":"A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer","source_id_and_acronym":"NCT06038578","lead_sponsor":"Toray Industries, Inc","biomarkers":" CAPRIN1","pipe":"","alterations":" ","tags":["CAPRIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Cyramza (ramucirumab) • TRK-950"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-21"},{"id":"9c255554-467f-443d-b9bf-0883f980d302","acronym":"SGNB6A-001","url":"https://clinicaltrials.gov/study/NCT04389632","created_at":"2021-08-12T17:53:41.583Z","updated_at":"2025-02-25T13:53:17.348Z","phase":"Phase 1","brief_title":"A Study of SGN-B6A in Advanced Solid Tumors","source_id_and_acronym":"NCT04389632 - SGNB6A-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)"],"overall_status":"Recruiting","enrollment":" Enrollment 824","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-20"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"4bf8a0e4-ad61-4bd3-8b19-15b271d96a0b","acronym":"D9750C00001","url":"https://clinicaltrials.gov/study/NCT06005493","created_at":"2023-08-22T15:08:52.377Z","updated_at":"2025-02-25T14:10:00.557Z","phase":"Phase 1/2","brief_title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06005493 - D9750C00001","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive • CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive • CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD5863"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/16/2026","primary_completion_date":" 12/16/2026","study_txt":" Completion: 12/16/2026","study_completion_date":" 12/16/2026","last_update_posted":"2025-02-18"},{"id":"1f5594ee-af51-418a-a186-3e2ddd1431f1","acronym":"BG-68501-101","url":"https://clinicaltrials.gov/study/NCT06257264","created_at":"2024-02-14T00:28:17.958Z","updated_at":"2025-02-25T14:18:45.977Z","phase":"Phase 1","brief_title":"A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors","source_id_and_acronym":"NCT06257264 - BG-68501-101","lead_sponsor":"BeiGene","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 03/11/2024","start_date":" 03/11/2024","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-17"},{"id":"40d264c0-ef98-4585-8486-d32526145561","acronym":"","url":"https://clinicaltrials.gov/study/NCT06123338","created_at":"2023-11-08T22:13:20.652Z","updated_at":"2025-02-25T14:42:29.112Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer","source_id_and_acronym":"NCT06123338","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-14"},{"id":"bcfa1353-7be6-4150-b82c-bf13212f8a0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836584","created_at":"2023-05-01T14:03:52.795Z","updated_at":"2025-02-25T15:13:28.038Z","phase":"Phase 2","brief_title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","source_id_and_acronym":"NCT05836584","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 12/06/2023","start_date":" 12/06/2023","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-13"},{"id":"3a138d15-6bca-4eff-8361-765e025c0dc8","acronym":"FORTITUDE-101","url":"https://clinicaltrials.gov/study/NCT05052801","created_at":"2021-09-22T11:53:35.151Z","updated_at":"2025-02-25T16:38:37.071Z","phase":"Phase 3","brief_title":"Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression","source_id_and_acronym":"NCT05052801 - FORTITUDE-101","lead_sponsor":"Amgen","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 overexpression • FGFR2b overexpression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 547","initiation":"Initiation: 03/07/2022","start_date":" 03/07/2022","primary_txt":" Primary completion: 08/18/2025","primary_completion_date":" 08/18/2025","study_txt":" Completion: 08/18/2025","study_completion_date":" 08/18/2025","last_update_posted":"2025-02-07"},{"id":"60529635-af59-4ddd-9192-b5ec25989186","acronym":"","url":"https://clinicaltrials.gov/study/NCT04661150","created_at":"2021-01-19T20:42:55.568Z","updated_at":"2025-02-25T16:38:08.739Z","phase":"Phase 2","brief_title":"A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction","source_id_and_acronym":"NCT04661150","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • capecitabine • oxaliplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/12/2021","start_date":" 03/12/2021","primary_txt":" Primary completion: 05/08/2023","primary_completion_date":" 05/08/2023","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-06"},{"id":"d0aa4f16-7694-44b7-8f9e-f75259b43f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT05544929","created_at":"2022-09-19T14:56:40.664Z","updated_at":"2025-02-25T16:39:18.617Z","phase":"Phase 1","brief_title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","source_id_and_acronym":"NCT05544929","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 02/20/2026","primary_completion_date":" 02/20/2026","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2025-02-06"},{"id":"b9a406bd-d975-4b31-a433-86da8522fc92","acronym":"TAS-120-202","url":"https://clinicaltrials.gov/study/NCT04189445","created_at":"2021-01-19T19:00:59.221Z","updated_at":"2025-02-25T16:44:46.191Z","phase":"Phase 2","brief_title":"Futibatinib in Patients With Specific FGFR Aberrations","source_id_and_acronym":"NCT04189445 - TAS-120-202","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 11/11/2024","primary_completion_date":" 11/11/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-05"},{"id":"3c19bae1-0bb5-4981-9c9a-f622527c42f9","acronym":"MCLA-158-CL01","url":"https://clinicaltrials.gov/study/NCT03526835","created_at":"2023-02-28T17:01:26.541Z","updated_at":"2025-02-25T17:36:01.506Z","phase":"Phase 1/2","brief_title":"A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03526835 - MCLA-158-CL01","lead_sponsor":"Merus N.V.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • petosemtamab (MCLA-158)"],"overall_status":"Recruiting","enrollment":" Enrollment 523","initiation":"Initiation: 05/02/2018","start_date":" 05/02/2018","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-01-29"},{"id":"1eead00e-edcb-481b-9a08-390ddb32d124","acronym":"CAMILLA","url":"https://clinicaltrials.gov/study/NCT03539822","created_at":"2021-10-27T20:54:20.716Z","updated_at":"2025-02-25T15:07:39.664Z","phase":"Phase 1/2","brief_title":"Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies","source_id_and_acronym":"NCT03539822 - CAMILLA","lead_sponsor":"Anwaar Saeed","biomarkers":" MSI","pipe":" | ","alterations":" RAS wild-type","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Cabometyx (cabozantinib tablet) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 10/22/2018","start_date":" 10/22/2018","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2025-01-14"},{"id":"e1db77e0-90c7-4f64-afe7-e9f653e16ebf","acronym":"ARTEMIDE-Gastric01","url":"https://clinicaltrials.gov/study/NCT06764875","created_at":"2025-02-26T07:06:51.440Z","updated_at":"2025-02-26T07:06:51.440Z","phase":"Phase 3","brief_title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","source_id_and_acronym":"NCT06764875 - ARTEMIDE-Gastric01","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 840","initiation":"Initiation: 03/28/2025","start_date":" 03/28/2025","primary_txt":" Primary completion: 04/27/2029","primary_completion_date":" 04/27/2029","study_txt":" Completion: 12/09/2030","study_completion_date":" 12/09/2030","last_update_posted":"2025-01-09"},{"id":"47c94276-aadc-4f56-b0e4-df2a44de0e7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04900818","created_at":"2021-05-25T18:52:39.848Z","updated_at":"2025-02-25T14:16:01.935Z","phase":"Phase 1","brief_title":"Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04900818","lead_sponsor":"I-Mab Biopharma US Limited","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • givastomig (TJ-CD4B)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 06/29/2021","start_date":" 06/29/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-01-03"},{"id":"6ae1af87-4593-48e3-aff5-d1191e4709dc","acronym":"TORCH-G","url":"https://clinicaltrials.gov/study/NCT06728657","created_at":"2025-02-26T07:20:14.599Z","updated_at":"2025-02-26T07:20:14.599Z","phase":"Phase 2","brief_title":"Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma","source_id_and_acronym":"NCT06728657 - TORCH-G","lead_sponsor":"Fudan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-12-11"},{"id":"9cbf2f0f-79e3-4928-a4ed-5ed00dfa5bc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06713993","created_at":"2025-02-26T10:41:48.420Z","updated_at":"2025-02-26T10:41:48.420Z","phase":"","brief_title":"Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer","source_id_and_acronym":"NCT06713993","lead_sponsor":"Semmelweis University","biomarkers":" IL6 • GDF15 • IGF1","pipe":"","alterations":" ","tags":["IL6 • GDF15 • IGF1"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/10/2024","start_date":" 09/10/2024","primary_txt":" Primary completion: 09/30/2029","primary_completion_date":" 09/30/2029","study_txt":" Completion: 09/10/2034","study_completion_date":" 09/10/2034","last_update_posted":"2024-12-03"},{"id":"dfa37710-8128-4c60-aefe-7507a106a2e0","acronym":"MK3475-A53","url":"https://clinicaltrials.gov/study/NCT05379972","created_at":"2022-05-18T11:57:02.291Z","updated_at":"2025-02-25T16:17:42.708Z","phase":"Phase 2","brief_title":"Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers","source_id_and_acronym":"NCT05379972 - MK3475-A53","lead_sponsor":"University of Colorado, Denver","biomarkers":" HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4","pipe":" | ","alterations":" HRD","tags":["HER-2 • BRCA1 • BRCA2 • PTEN • HRD • BAP1 • KMT2D • ATRX • CHEK2 • FANCA • BRIP1 • RAD50 • MLL2 • CHEK1 • BARD1 • NBN • WRN • FANCG • ABRAXAS1 • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-11-26"},{"id":"a35ae63d-7bfa-40bf-b911-fec1b0dea308","acronym":"DECIPHER","url":"https://clinicaltrials.gov/study/NCT05965479","created_at":"2023-07-31T17:08:57.339Z","updated_at":"2025-02-25T15:01:01.413Z","phase":"Phase 2","brief_title":"Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer","source_id_and_acronym":"NCT05965479 - DECIPHER","lead_sponsor":"University of Southampton","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/10/2024","start_date":" 04/10/2024","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-11-11"},{"id":"da8385f8-d966-4338-afb8-29be3c58c4e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05650827","created_at":"2025-03-03T11:24:03.773Z","updated_at":"2025-03-03T11:24:03.773Z","phase":"","brief_title":"Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer","source_id_and_acronym":"NCT05650827","lead_sponsor":"Rigshospitalet, Denmark","biomarkers":" IFNG • IL6 • TNFA • IL10 • CRP","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 02/24/2023","start_date":" 02/24/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-11-05"},{"id":"990e56a9-fdb3-4de5-b212-83f4d38144b8","acronym":"DESTINY-Gastric04","url":"https://clinicaltrials.gov/study/NCT04704934","created_at":"2021-01-19T20:51:20.427Z","updated_at":"2025-02-25T14:59:37.131Z","phase":"Phase 3","brief_title":"Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)","source_id_and_acronym":"NCT04704934 - DESTINY-Gastric04","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Cyramza (ramucirumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 05/21/2021","start_date":" 05/21/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-10-24"},{"id":"59848edf-80f8-486e-a558-b5247dba69ec","acronym":"HEPATOXALI","url":"https://clinicaltrials.gov/study/NCT06649474","created_at":"2025-02-26T10:15:50.734Z","updated_at":"2025-02-26T10:15:50.734Z","phase":"","brief_title":"Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1","source_id_and_acronym":"NCT06649474 - HEPATOXALI","lead_sponsor":"University Hospital, Clermont-Ferrand","biomarkers":" HMGB1","pipe":"","alterations":" ","tags":["HMGB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/06/2024","start_date":" 09/06/2024","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-10-18"}]